Biomay Announces its Successful Support of Approval of First CRISPR/Cas9-based Therapy
(January 25th, 2024) Biomay, a biotech contract development and manufacturing organization based in Vienna, Austria,
announces successful completion of an FDA inspection qualifying Biomay as a cGMP manufacturer
and supplier of recombinant nuclease Cas9 for use in gene editing therapies.
Biomay and RBPS-Technologies Sign Agreement for GMP Minicircle DNA
(July 27th, 2009) Biomay and RBPS-Technologies announce their manufacturing cooperation for production of GMP-grade minicircle DNA. The companies are now offering a contract manufacturing service to third parties to supply minicircles in both clinical quality for use in clinical trials and research quality.
> More info